Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Anticonvulsant or Opioid or [[:Category:Ophthalmic_antihistamines|Ophthalmic antihistamine]]

Use the filters below to narrow your results.

generic:
Codeine (2)
brand:
None (12)
classes: (Click arrow to add another value)
mechanism:
Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · Sodium channel blocker (2)
uses:
None (48) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000011D7-QINU`"', '"`UNIQ--vote-000011D8-QINU`"' (1) · '"`UNIQ--vote-00001286-QINU`"' (1)
starting dose:
None (48) · Adult: 15–60 mg every 4 hours as needed. (1) · Ophthalmic 1 drop in each eye every 8-12 hours (1) · Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1)
preparations:
None (48) · 0.025%, 0.035% ophthalmic solutions (1) · 0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
None (48) · 1 drop per eye q8-12h (1) · 360 mg/day (1) · Once daily (Pataday 0.7%); BID (other ophthalmic) (1)
routes:
None (48) · intranasal (1) · PO (only formulation marketed in the US). (1) · Topical ophthalmic (2)
onset:
None (48) · 30–60 min (PO) (1) · Symptom relief within 30-60 minutes (1) · Within minutes (1)
duration:
None (48) · 24 hours (0.7% formulation); 8-12 hours (lower-strength) (1) · 4–6 hours (1) · 8-12 hours (1)
halflife:
None (48) · 2.5–3 hours (1) · Not meaningfully described for ophthalmic use'"`UNIQ--ref-00001287-QINU`"' (1) · ~3 hours (systemic, when measurable; topical action dominates)'"`UNIQ--ref-000011D9-QINU`"' (1)
bioavailability:
None (48) · Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)
pregnancy:
None (48) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (48) · OTC (Pataday ophthalmic) and [[USLegal:Prescription only|Rx-only]] (Patanase intranasal) in US (1) · OTC in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)

Showing below up to 51 results in range #1 to #51.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"